Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Interdict Bio MYC inhibitor
- Development stage
- Preclinical
- Lead developer
- Interdict Bio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Interdict Bio's lead program is an orally bioavailable small molecule designed to treat MYC-dependent solid tumors. Utilizing the company's proprietary Interdictor™ platform, the drug targets the historically 'undruggable' MYC oncogenic transcription factor by a novel mechanism: stalling its translation. The molecule binds to the ribosomal peptidyl transferase center (PTC) and engages in sequence-selective interactions with the MYC nascent polypeptide as it is being synthesized. This context-dependent inhibition prevents the production of the MYC protein, which is overactivated in approximately 70% of cancers but difficult to target directly due to its disordered structure and rapid turnover. The program is currently in the IND-enabling phase of development.
- Other names
- MYC programInterdictor MYC inhibitorMYC
02
Targets
PTC (50S ribosomal peptidyl transferase center)80S ribosome (Ribosome and ribosomal components)
Beyond the preview
Go deeper on Interdict Bio MYC inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Interdict Bio MYC inhibitor.